Medicinal cannabis evidence topics

New Zealand’s medicinal cannabis scheme is a regulated pharmaceutical pathway, not a general licence to use cannabis. Under the Misuse of Drugs Act, access starts with a prescription from a medical practitioner, and the medicines that can be supplied are manufactured pharmaceuticals that meet GMP standards and have been verified by the Ministry of Health. The most common misunderstanding is that “legal medicinal cannabis” means a patient can legally smoke raw plant material or buy unregulated preparations. The legal item is a manufactured pharmaceutical; even dried flower is prescribed and dispensed through a pharmacy.

This hub collects the evidence and safety questions patients and whānau raise. It explains how to read the evidence, what the law requires, and how to judge the claims you will see. It does not give dosing or treatment advice. The linked directory below groups the full set of evidence topics, and each page answers one question.

How the evidence is organised

The directory below groups the evidence and safety pages you can read next, and the checks in this article explain how to weigh what you find.

The legal and regulatory basis for medicinal cannabis is the Misuse of Drugs Act, and the operating framework is the Medicinal Cannabis Scheme run by the Ministry of Health. Under that scheme, a prescription from a medical practitioner is required, and medicines must meet GMP standards and be verified by the Ministry. The scheme is administered by the Medicinal Cannabis Agency (MCA), which sits within Medsafe, the country’s medicines regulator. The rules were set out in the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, which came into force on 1 April 2020. That date is the effective legal baseline for all medicine approvals and prescribing under the scheme.

What is regulated medicinal cannabis?

Under New Zealand law, medicinal cannabis is a pharmaceutical pathway, not a general licence to use cannabis. The Misuse of Drugs Act 1975 and the 2019 regulations) allow a medical practitioner to prescribe a manufactured cannabis medicine, and the medicine must meet Good Manufacturing Practice (GMP) standards and be verified by the Ministry of Health. The Medicinal Cannabis Agency (MCA), which sits inside Medsafe, issues licences and manages the scheme. The NZ Formulary lists medicines that meet these standards, and prescribers use it as the official reference. The key legal boundary: “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated preparations. The legal item is a manufactured pharmaceutical; raw flower, when prescribed, is dispensed through a pharmacy, not a dispensary.

Understanding the evidence

The evidence base for medicinal cannabis is not uniform. Some conditions have strong systematic review support, some have moderate evidence, and others are supported mainly by anecdote. The Medicinal Cannabis Scheme, run by the Ministry of Health and regulated by Medsafe, only legalises access through a prescription from a medical practitioner. Medicines must meet GMP standards and be verified by the Ministry of Health (Medsafe, 2020). The NZ Formulary lists cannabis medicines with prescribing guidance, but it does not rank them for efficacy; the clinician’s judgement and the patient’s response remain central.

How to read the evidence

When you read a claim about medicinal cannabis, check four things:

Source type, Systematic reviews and peer-reviewed clinical guidance carry more weight than single case reports or medicine marketing.
Outcome measured, Pain scores, seizure frequency, quality of life, and adverse events are different endpoints; a preparation may help one and not another.
Population studied, Evidence from cancer trials may not transfer to chronic pain or epilepsy.
Regulatory status, Only medicines verified under the Medicinal Cannabis Scheme and listed on the NZ Formulary) are legal; verification does not equal efficacy for every condition.

These checks apply to every page in this evidence hub. The collection hub explains how to compare preparations; this page maps the evidence.

What this hub covers

Medicinal cannabis is a regulated pharmaceutical pathway under the Misuse of Drugs Act, not a general licence to use cannabis. Since the Medicinal Cannabis Scheme came into force on 1 November2020, patients can access quality-assured medicines through a prescription from a medical practitioner, and medicines must meet GMP standards and be verified by the Ministry of Health. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated preparations. The legal item is a manufactured pharmaceutical, and raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary.

This hub collects the evidence topics that patients, whānau and clinicians ask about. It explains how to read the evidence and where to go next. It does not replace a consultation with a prescriber.

How to use this hub

Each article in this section answers one practical question. Start with the patient pathway if you are new to the system. If you already know the pathway and want to compare preparations, go to the preparation comparison. If you are trying to judge whether a study or a preparation claim is reliable, read the evidence checks first. The directory below the article links to every page in the collection, and each page links back to its neighbours.

Before you rely on any page in this hub, apply three checks:

Is the claim tied to a named source and year? The regulatory and prescribing landscape changes quickly. If a page does not cite a source, treat the claim as unverified.
Is the evidence established, emerging, or absent? Established evidence is supported by systematic reviews or large clinical trials. Emerging evidence is promising but not conclusive. Absence of good evidence means no reliable human data, and any marketing claim should be treated as advertising, not fact.
Is it legal, right now? The Medicinal Cannabis Scheme under the Misuse of Drugs Act sets the only legal pathway. A preparation that is legal elsewhere may not be verified here. Check the effective date of any legal statement.

Understanding the evidence base

Medicinal cannabis evidence is not one block. It splits into three tiers: indications where clinical trials are strong enough to support prescribing, conditions where the evidence is mixed or early, and conditions where claims outrun the research. The regulatory framework follows the international evidence, and the practical question is not “does cannabis work?” but “for which condition, at which dose, and in which formulation?”

Conditions with stronger evidence

The strongest evidence, according to systematic reviews and guidance cited by the Ministry of Health, supports cannabis-based medicines for chronic pain in adults, particularly neuropathic pain, and for spasticity in multiple sclerosis (nabiximols, a specific preparation not currently on the NZ market). Evidence for chemotherapy-induced nausea and vomiting is also reasonably consistent, and there is moderate evidence for symptom management in palliative care. These are the areas where a prescriber is most likely to consider a trial.

Conditions with limited or mixed evidence

Evidence is more limited for conditions such as anxiety, post-traumatic stress disorder, depression, insomnia, and inflammatory bowel disease. Some small trials and observational data suggest benefit, but systematic reviews often note high risk of bias, small sample sizes, or inconsistent outcomes. For these conditions, the NZ Formulary and Ministry of Health guidance do not list medicinal cannabis as a first-line treatment; it is usually considered only after conventional options have failed and under specialist supervision. Refractory childhood epilepsy is a special case: there is stronger evidence for CBD-dominant preparations in specific syndromes, but medicines are still prescribed on a case-by-case basis.

Claims outside the evidence base

There are also claims that currently sit outside the evidence base. These include cannabis as a cure for cancer, reversal of neurodegenerative disease, or a reliable treatment for mental health conditions such as depression or anxiety. Some patients report benefit, but controlled studies are limited or mixed. The Ministry of Health does not verify cannabis for these uses, and the NZ Formulary notes limited evidence. Marketing claims that go beyond the verified indications are not evidence.

The legal pathway

The current pathway for patients is set by the Misuse of Drugs (Medicinal Cannabis) Regulations2019, which came into effect on1 April2020. Under these regulations, a medical practitioner can prescribe a CBD or THC medicine that meets GMP standards and has been notified to the Ministry of Health under the Medicinal Cannabis Scheme. The Ministry runs the scheme through the Medicinal Cannabis Agency, which sits within Medsafe. Prescriptions are issued through normal prescription channels, and medicines are dispensed by a licensed pharmacist. The NZ Formulary includes cannabis medicine monographs and is the official prescribing guide. The evidence base is summarised by the NZ Formulary, Healthify, and systematic reviews, but the clinical decision always rests with the prescriber.

One fact no competitor’s page can duplicate

The Medicinal Cannabis Scheme came into force on1 April2020 under regulations specific to this country, and every legal medicine must be verified by the Ministry of Health through the MCA before a pharmacist can dispense it, no other jurisdiction shares that exact regulatory date, agency structure, and pharmacy-only dispensing rule.